Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Combined With Nab-paclitaxel and Carboplatin for Neoadjuvant Therapy in Borderline Resectable ESCC
NCT07638436Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sun Yat-sen University. Started Jun 2026; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07638436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07638436.